AmoyDx(SZ:300685) Zhi Tong Cai Jing·2025-10-09 09:19Core Viewpoint - The investment by the company in Sailu Medical is a strategic move to strengthen its position in the gene testing industry and enhance collaboration within the supply chain [1][2] Group 1: Investment Details - The company has signed a B-round capital increase agreement with Sailu Medical, investing 50 million yuan, of which 55,701 yuan will be added to the registered capital, and the remainder will be included in the capital reserve [1] - Following this investment, the company will hold a 2.3810% stake in Sailu Medical [1] Group 2: Industry Context - Sailu Medical operates in the upstream of the gene sequencing industry, characterized by high technical intensity and significant R&D barriers [1] - The company has developed a self-controlled sequencing technology platform and has complete R&D and production capabilities for gene sequencing instruments and related consumables [1] - The SalusPro gene sequencer received approval as a Class III medical device in January 2025 [1] Group 3: Strategic Implications - The investment aligns with the accelerating trend of domestic substitution in gene sequencing, leveraging Sailu Medical's core advantages in sequencing platforms [2] - This collaboration is expected to enhance the company's competitiveness in the industry and promote the integration of upstream and downstream resources [2] - The initiative aims to accelerate innovation and clinical transformation of cutting-edge technologies, providing more precise and accessible gene testing solutions for patients [2] - It will further solidify the company's leading position in the field of precision medicine for tumors [2]